Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 1 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Nkarta Inc | NKTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 6.82 | 07:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 6.82 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 1 | 1 | - | 1.28 - 16.24 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 06:54:56 | 1 | $ 6.80 | USD |
Nkarta Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 334.67M | 49.07M | - | 0 | -117.5M | -2.39 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Nkarta News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NKTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.70 | 7.96 | 6.47 | 7.17 | 897,978 | -0.88 | -11.43% |
| 1 Month | 11.585 | 11.8388 | 6.47 | 8.55 | 1,018,607 | -4.77 | -41.13% |
| 3 Months | 10.54 | 16.24 | 6.47 | 10.32 | 1,020,864 | -3.72 | -35.29% |
| 6 Months | 2.00 | 16.24 | 1.86 | 8.58 | 1,528,029 | 4.82 | 241.00% |
| 1 Year | 4.53 | 16.24 | 1.28 | 5.80 | 1,477,623 | 2.29 | 50.55% |
| 3 Years | 32.92 | 40.64 | 1.28 | 10.65 | 986,614 | -26.10 | -79.28% |
| 5 Years | 54.75 | 79.16 | 1.28 | 12.34 | 827,135 | -47.93 | -87.54% |
Nkarta Description
| Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. It is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The company's operations are based in South San Francisco, California and it operates in one segment. |
